Search Results

, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease , obesity, diabetes, chronic pain and addiction. They highlighted the importance of fine-tuning the approach to suit different diseases and interdisciplinary The discussion also emphasized the need for a disease-specific approach, considering the clinical context

Retreat Program < Back to schedule Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease

Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases

Join me and learn more about how Kari studies GPCRs in basal ganglia circuits following chronic alcohol

Program < Back to schedule Biased agonism at the GLP-1 receptor: from structure to animal models of disease

Sponsors GPCR Retreat Program < Back to schedule Genetic Deletion of Atypical VGLUT3 Rescues Huntington’s Disease coupled receptors and their role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases

at the University of Bonn, Germany, working initially on the role of prostaglandin receptor EP4 in chronic

Initial impairment of synaptic functions, which occurs early in Alzheimer’s disease, and subsequent massive ADGRC3 are required for the restoration of glutamatergic synapses in prefrontal cortical neurons of chronically My research focus is the mechanisms of neural circuit development, function and disease."

McGill, his laboratory has two main axes of research: 1) Studying interindividual vulnerability to chronic

and Genetic Preclinical Models of Ghrelin Receptor Functional Selectivity to Investigate Metabolic Disease GPCR biased signaling to design/develop new pharmacotherapeutics to treat reward- and metabolism-based diseases novel GPCR pharmacotherapies that improve efficacy and minimize side effects for diet-induced metabolic diseases

characterized the role of RGS4 and RGS5 in airway hyperresponsiveness and lung fibrosis in acute and chronic

< GPCR News < GPCRs in Oncology and Immunology Deciphering the genetic landscape of lumpy skin disease through comprehensive genome sequence analysis in India Published date May 23, 2024 Abstract "Lumpy Skin Disease (LSD), a poxvirus disease affecting cattle, emerged in India in 2019 and intensified in 2022, resulting , V Gairola, D Poloju, S Gulzar, K P Singh, R K Singh, G K Sharma Tags Genome sequence , Lumpy skin disease

, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease , obesity, diabetes, chronic pain and addiction. Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with

, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease , obesity, diabetes, chronic pain and addiction. Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with

July 3, 2024 Abstract "Development of type 2 diabetes mellitus (T2DM) is associated with low-grade chronic

McGill, his laboratory has two main axes of research: 1) Studying interindividual vulnerability to chronic

interested in characterizing novel G protein-coupled receptors (GPCRs) ligands for the treatment of chronic

Recent evidence indicates that GPR15 may be associated with modulation of the chronic inflammatory response

implications of this theory are discussed in relation to mesothelioma and lung cancer associated with chronic

reaction networks are an important and emerging tool for the study of cell signaling networks involved in disease One promising potential application of such mathematical models is the study of how disease-causing mutations promote the signaling phenotype that contributes to the disease. and use model-driven explorations to uncover and explore multiple new areas for investigating this disease revealed the potential for previously unknown qualitative differences between seemingly interchangeable disease-promoting

Indian Institute of Science, Bangalore, India, to investigate the mechanisms behind rare mitochondrial diseases at the Cleveland Clinic in Ohio, USA, studying the gut microbiome and its impact on cardiovascular disease gut microbe-derived metabolite called phenylacetylglutamine (PAG), which is linked to cardiovascular disease as targets for more than one-third of all prescribed drugs currently used in the treatment of human diseases

Administration of ITA protects against inflammatory diseases and blockade of ITA production enhances mechanisms, and conjecture a rationale for developing ITA-based therapeutics to treat inflammatory diseases Dan Ye , Pu Wang , Lei-Lei Chen , Kun-Liang Guan , Yue Xiong Tags IRG1/ACOD1 , cancer , inflammatory diseases

Among 41 patients treated at RP2D, a measurable residual disease-negative complete remission (MRD- CR 76%, without differences in MRD- CR rates, OS, or EFS between patients with or without FLT3-mutated disease Benefit was limited to patients with intermediate-risk disease (univariate analysis: P = .01 for OS; improves OS and EFS relative to CLAG-M alone, with benefits primarily in patients with intermediate-risk disease

mechanisms underlying biased agonism at GPCRs and its contribution inflammation and cardiovascular disease His clinical focus is on pulmonary arterial hypertension, a disease of the pulmonary arterioles that causes right heart failure, and he serves as co-director of the Duke Pulmonary Vascular Disease Center

the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics that interdict diseases basis of a new technology-based start-up company, HeptOME , to help screen and develop novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles.

the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics that interdict diseases basis of a new technology-based start-up company, HeptOME , to help screen and develop novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles.

the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics that interdict diseases basis of a new technology-based start-up company, HeptOME , to help screen and develop novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles.

the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for metabolic diseases Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases